

5098)

8EHQ-0801-14999

RECEIVED  
OFFICE

2001 AUG 23

DuPont Haskell Laboratory  
for Health and Environmental Sciences  
Elkton Road, P.O. Box 50  
Newark, DE 19714-0050



August 22, 2001

Via Federal Express

Document Control Office (7407)  
Room G99 East Tower  
Attention: 8(e) Coordinator  
Office of Pollution Prevention and Toxics  
U.S. Environmental Protection Agency  
401 M Street SW  
Washington, D.C. 20460-0001

Contain NO CBI

Dear 8(e) Coordinator:

4-Iodo-3, 3, 4, 4-tetrafluoro-1-butene  
CAS # 33831-83-3

This letter is to inform you of the results of a recently completed acute rat dermal toxicity study with the above referenced test material.

The test material, at the limit dose of 2000 mg/kg of body weight, was applied dermally to a group of 5 male and 5 female Wistar rats for 24 hours. After exposure, rats were observed daily for clinical signs and weighed weekly during a 2-week post exposure observation period. Macroscopic examination was performed after terminal sacrifice.

No mortality occurred at 2000 mg/kg. Lethargy, salivation, hunched posture, quick breathing, chromodacryorrhea, piloerection, uncoordinated movements, and/or ptosis were observed. The animals recovered from these clinical signs between days 1 and 5 after treatment. General erythema, scales, scabs and/or swelling were seen in the treated skin-area during the observation period. There was no effect on body weight and no abnormalities were found on macroscopic examination. The dermal LD50 was greater than 2000 mg/kg of body weight.

Under these experimental conditions, the clinical observations described above appear to be reportable, based upon guidance given in the EPA TSCA Section 8(e) Reporting Guide (June 1991).

Sincerely,

A. Michael Kaplan, Ph.D.  
Director - Regulatory Affairs



AMK/RV:clp  
(302) 366-5260



1994-1995